Back to Search
Start Over
Do we need a new P2Y12 receptor antagonist?
- Source :
- European Heart Journal, European Heart Journal, Oxford University Press (OUP): Policy B, 2020, 41 (33), pp.3141-3143. ⟨10.1093/eurheartj/ehz862⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). Methods and results In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcutaneous selatogrel (8 mg, n = 114; or 16 mg, n = 115) was compared with placebo (n = 116) (ClinicalTrials.gov: NCT03384966). Platelet aggregation was assessed over 24 h (VerifyNow assay) and 8 h (light transmittance aggregometry; LTA). Pharmacodynamic responders were defined as patients having P2Y12 reaction units (PRU)
- Subjects :
- P2Y12 Receptor Antagonists
[SDV]Life Sciences [q-bio]
P2Y12 receptor antagonist
Organophosphonates
030204 cardiovascular system & hematology
Pharmacology
030226 pharmacology & pharmacy
Coronary artery disease
03 medical and health sciences
0302 clinical medicine
Clinical Research
Medicine
Humans
AcademicSubjects/MED00200
Platelet aggregation
Pharmacokinetics
Purinergic P2Y Receptor Antagonists
ComputingMilieux_MISCELLANEOUS
business.industry
Syndrome
3. Good health
Editor's Choice
Pyrimidines
Pharmacodynamics
Thrombosis and Antithrombotic Therapy
Selatogrel
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- Language :
- English
- ISSN :
- 0195668X and 15229645
- Database :
- OpenAIRE
- Journal :
- European Heart Journal, European Heart Journal, Oxford University Press (OUP): Policy B, 2020, 41 (33), pp.3141-3143. ⟨10.1093/eurheartj/ehz862⟩
- Accession number :
- edsair.doi.dedup.....6a3fcb56aaebc66f4018a3c04fd68652